Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2018 / Article

Corrigendum | Open Access

Volume 2018 |Article ID 9705495 | 1 page | https://doi.org/10.1155/2018/9705495

Corrigendum to “Pharmacological Basis for Use of Selaginella moellendorffii in Gouty Arthritis: Antihyperuricemic, Anti-Inflammatory, and Xanthine Oxidase Inhibition”

Received13 May 2018
Accepted28 May 2018
Published05 Jul 2018

In the article titled “Pharmacological Basis for Use of Selaginella moellendorffii in Gouty Arthritis: Antihyperuricemic, Anti-Inflammatory, and Xanthine Oxidase Inhibition” [1], there was a missing grant number. Accordingly, the Acknowledgments section should be corrected as follows:

This work was funded by China Postdoctoral Science Foundation (2016M601237), the Natural Science Foundation Project (30470193), the Scientific Research Foundation Project of the Education Department of Hubei Province (Q20142007), Natural Science Foundation of Hubei Province (2013CFC055), and the Young Plan Project of Hubei University of Chinese Medicine (XJ2014KJ008).

References

  1. P. Zhao, K. Chen, G. Zhang, G. Deng, and J. Li, “Pharmacological basis for use of Selaginella moellendorffii in gouty arthritis: antihyperuricemic, anti-inflammatory, and xanthine oxidase inhibition,” Evidence-Based Complementary and Alternative Medicine, vol. 2017, 10 pages, 2017. View at: Publisher Site | Google Scholar

Copyright © 2018 Ping Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

434 Views | 207 Downloads | 1 Citation
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.